Cell and Gene Manufacturing and Logistics

31. Why Academic Centers Reach The Clinic Faster 10/29/2025

    In this segment of Cell & Gene Live, Designing Early Manufacturing For Long-Term Success In CGT, Raymond Luke, Senior Director of MSAT at Verismo Therapeutics and Todd Luman, Executive Director of Process and Product Development at Allogene, Luman explains that academic institutions often move faster in Phase 1 because many trials are investigator-initiated, allowing streamlined oversight and quicker regulatory engagement, though similar pathways for sponsor-led programs don’t yet exist in the U.S. or EU.

32. Early Development Choices Define Scalability And Product Quality In CGT 10/29/2025

    In this segment of Cell & Gene Live, Designing Early Manufacturing For Long-Term Success In CGT, Raymond Luke, Senior Director of MSAT at Verismo Therapeutics and Todd Luman, Executive Director of Process and Product Development at Allogene stress that early-stage process decisions have lasting downstream effects on product quality, scalability, and speed to clinic.

33. Building Strong Data Foundations And Smart Logistics For Scalable CGT Development 10/29/2025

    In this segment of Cell & Gene Live, Designing Early Manufacturing For Long-Term Success In CGT, Raymond Luke, Senior Director of MSAT at Verismo Therapeutics and Todd Luman, Executive Director of Process and Product Development at Allogene emphasize that early investment in analytics and structured data collection is essential to guide scale-up and regulatory success. 

34. Strategize For Success With Single-Use Biomanufacturing Systems 10/29/2025

    Single-use technologies are reshaping biomanufacturing workflows. Discover the key stages of implementation and how strategic choices drive success across the entire production process.

35. Are You Still Evaluating CMOs When You Really Need A CDMO? 10/29/2025

    Outsourcing adds capacity and specialized knowledge to your supply chain. But contractors come in several types. Here's how to pick the right one.

36. Partner Case Study: Accelerating Gene Editing Manufacturing 10/28/2025

    Beam Therapeutics partnered with ElevateBio to manufacture BEAM-101, a novel base editing therapy for sickle cell disease, advancing rapid, high-quality production towards clinical trials.

37. Solving The Sequencing Puzzle: Speed, Cost, And Quality 10/28/2025

    Next-generation sequencing (NGS) accelerates therapy development by enabling rapid, cost-effective DNA/RNA analysis crucial for cell and gene therapies, process optimization, and impurity detection.

38. Streamlining Analytical Release Testing With Faster, Smaller Workflows 10/28/2025

    Reducing turnaround times and sample volumes in release testing can accelerate cell therapy manufacturing, preserve product yield, and improve patient outcomes.

39. Optimizing CGT With Lean Principles 10/28/2025

    See the outline of lean manufacturing strategies for cell and gene therapies, emphasizing digitization, automation, and hybrid batch records to enhance efficiency and scalability.

40. Genetic Medicines, From Idea To Impact 10/28/2025

    This presentation explores how ElevateBio combines cutting-edge gene editing technologies with cell therapy and mRNA manufacturing expertise to enable partners through development and commercialization.